Commentary on "Poor evidence for host-dependent regular RNA editing in the transcriptome of SARS-CoV-2".


Journal

Journal of applied genetics
ISSN: 2190-3883
Titre abrégé: J Appl Genet
Pays: England
ID NLM: 9514582

Informations de publication

Date de publication:
May 2022
Historique:
received: 28 01 2022
accepted: 16 02 2022
revised: 14 02 2022
pubmed: 14 3 2022
medline: 7 4 2022
entrez: 13 3 2022
Statut: ppublish

Résumé

Analysis of the SARS-CoV-2 transcriptome has revealed a background of low-frequency intra-host genetic changes with a strong bias towards transitions. A similar pattern is also observed when inter-host variability is considered. We and others have shown that the cellular RNA editing machinery based on ADAR and APOBEC host-deaminases could be involved in the onset of SARS-CoV-2 genetic variability. Our hypothesis is based both on similarities with other known forms of viral genome editing and on the excess of transition changes, which is difficult to explain with errors during viral replication. Zong et al. criticize our analysis on both conceptual and technical grounds. While ultimate proof of an involvement of host deaminases in viral RNA editing will depend on experimental validation, here, we address the criticism to suggest that viral RNA editing is the most reasonable explanation for the observed intra- and inter-host variability.

Identifiants

pubmed: 35279801
doi: 10.1007/s13353-022-00688-x
pii: 10.1007/s13353-022-00688-x
pmc: PMC8917825
doi:

Substances chimiques

Adenosine Deaminase EC 3.5.4.4

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-428

Informations de copyright

© 2022. The Author(s), under exclusive licence to Institute of Plant Genetics Polish Academy of Sciences.

Références

Nucleic Acids Res. 2022 Feb 22;50(3):1551-1561
pubmed: 35048970
J Virol. 2005 May;79(10):6291-8
pubmed: 15858013
Cell. 1988 Oct 21;55(2):255-65
pubmed: 3167982
J Virol. 2007 Jan;81(2):457-64
pubmed: 17020943
Sci Rep. 2020 Oct 20;10(1):17766
pubmed: 33082451
Nat Commun. 2014 Aug 27;5:4726
pubmed: 25158696
PLoS Biol. 2015 Sep 16;13(9):e1002251
pubmed: 26375597
Biochem Biophys Res Commun. 2021 Jan 29;538:35-39
pubmed: 33234239
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
Viruses. 2021 Mar 02;13(3):
pubmed: 33801257
J Virol. 2011 Aug;85(15):7594-602
pubmed: 21632763
Cell. 2003 Jun 13;113(6):803-9
pubmed: 12809610
Biochem Biophys Res Commun. 2006 Nov 10;350(1):214-9
pubmed: 16999936
Nat Struct Mol Biol. 2021 Sep;28(9):740-746
pubmed: 34381216
J Mol Cell Biol. 2021 Jul 6;13(3):225-227
pubmed: 33630074
PLoS Pathog. 2021 Jun 1;17(6):e1009596
pubmed: 34061905
Nat Protoc. 2020 Mar;15(3):1098-1131
pubmed: 31996844
PLoS One. 2020 Oct 2;15(10):e0237689
pubmed: 33006981
Nucleic Acids Res. 2009 Sep;37(17):5848-58
pubmed: 19651874
Curr Top Microbiol Immunol. 2012;353:163-95
pubmed: 21809195
Hepatology. 2005 Mar;41(3):626-33
pubmed: 15726649
J Biol Chem. 1991 Oct 25;266(30):20550-4
pubmed: 1939106
PLoS One. 2021 Feb 25;16(2):e0247128
pubmed: 33630927
J Cell Sci. 2017 Feb 15;130(4):745-753
pubmed: 28082424
Exp Cell Res. 2001 Jul 15;267(2):153-64
pubmed: 11426934
Genome Med. 2021 Feb 22;13(1):30
pubmed: 33618765
mSphere. 2020 Jun 24;5(3):
pubmed: 32581081
J Appl Genet. 2022 May;63(2):413-421
pubmed: 35179717
iScience. 2021 Feb 19;24(2):102116
pubmed: 33532709
Genes (Basel). 2021 Dec 23;13(1):
pubmed: 35052382
J Virol. 2008 Nov;82(21):10864-72
pubmed: 18753201
Natl Sci Rev. 2021 Dec 04;9(2):nwab220
pubmed: 35211321
J Interferon Cytokine Res. 2009 Sep;29(9):477-87
pubmed: 19715457
RNA. 1996 Mar;2(3):274-88
pubmed: 8608451
Cell Host Microbe. 2018 May 9;23(5):628-635.e7
pubmed: 29746834
Rev Med Virol. 2011 Jan;21(1):42-53
pubmed: 21294215
Elife. 2021 Aug 13;10:
pubmed: 34387545
Nat Commun. 2020 Nov 25;11(1):5986
pubmed: 33239633
Mol Cell Biol. 1995 Oct;15(10):5376-88
pubmed: 7565688
Genes (Basel). 2021 May 27;12(6):
pubmed: 34072181
BMC Evol Biol. 2019 Jul 23;19(1):149
pubmed: 31337330
J Gen Virol. 2005 Sep;86(Pt 9):2489-2494
pubmed: 16099907
PLoS Pathog. 2013 Aug;9(8):e1003565
pubmed: 23966862
Curr Issues Mol Biol. 2015;17:37-51
pubmed: 25502818
Mol Biol Evol. 2021 Jan 4;38(1):67-83
pubmed: 32687176
Science. 2008 Apr 11;320(5873):230-3
pubmed: 18403710
Emerg Microbes Infect. 2021 Dec;10(1):1777-1789
pubmed: 34402744
BMC Genet. 2009 Nov 26;10:75
pubmed: 19941656
PLoS One. 2021 Jul 23;16(7):e0255169
pubmed: 34297786
Sci Transl Med. 2020 Dec 9;12(573):
pubmed: 33229462
Curr Opin Immunol. 2011 Oct;23(5):573-82
pubmed: 21924887
Virus Evol. 2021 Sep 29;7(2):veab078
pubmed: 34642605
Sci Adv. 2020 Jun 17;6(25):eabb5813
pubmed: 32596474
J Biol Chem. 2005 Feb 4;280(5):3946-53
pubmed: 15556947
J Gen Virol. 2011 May;92(Pt 5):1228-1232
pubmed: 21289159
J Virol. 1991 Apr;65(4):1779-88
pubmed: 2002543
Front Microbiol. 2021 Oct 18;12:753823
pubmed: 34733263
J Biol Chem. 2013 Jun 14;288(24):17253-60
pubmed: 23640892

Auteurs

F Martignano (F)

Core Research Laboratory, ISPRO, 50139, Firenze, Italy.

S Di Giorgio (S)

German Cancer Research Center (DKFZ), Division of Immune Diversity, Foundation Under Public Law, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

G Mattiuz (G)

Department of Experimental and Clinical Medicine, University of Florence, 50139, Firenze, Italy.

S G Conticello (SG)

Core Research Laboratory, ISPRO, 50139, Firenze, Italy. silvestro.conticello@cnr.it.
Institute of Clinical Physiology, National Research Council, 56124, Pisa, Italy. silvestro.conticello@cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH